Download Files:
Products Details
Product Description
– CD161 (NKR-P1A) is a potent, selective and orally bioavailable bromodomain and extra-terminal (BET) bromodomain inhibitor with an IC50s of 28.2 nM and 7.2 nM for BRD4 BD1 and BRD4 BD2, respectively. CD161 has good anticancer activity[1].
Web ID
– HY-124596
Shipping
– Room temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C26H21N5O2
References
– [1]Zhao Y, et al. Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. J Med Chem. 2017 May 11;60(9):3887-3901.
CAS Number
– 1627716-22-6
Molecular Weight
– 435.48
SMILES
– CC1=NC(C2=CC=NC3=CC=CC=C23)=C4C(NC5=C4C=C(OC)C(C6=C(C)ON=C6C)=C5)=N1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Epigenetic Reader Domain
Pathway
– Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
